@article{10.1172/jci.insight.137869, author = {Marie-Julie Nokin AND Elodie Darbo AND Camille Travert AND Benjamin Drogat AND Aurélie Lacouture AND Sonia San José AND Nuria Cabrera AND Béatrice Turcq AND Valérie Prouzet-Mauleon AND Mattia Falcone AND Alberto Villanueva AND Haiyun Wang AND Michael Herfs AND Miguel Mosteiro AND Pasi A. Jänne AND Jean-Louis Pujol AND Antonio Maraver AND Mariano Barbacid AND Ernest Nadal AND David Santamaría AND Chiara Ambrogio}, journal = {JCI Insight}, publisher = {The American Society for Clinical Investigation}, title = {Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma}, year = {2020}, month = {8}, volume = {5}, url = {https://insight.jci.org/articles/view/137869}, abstract = {Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient stratification and for the identification of new therapeutic strategies, including enhancing the efficacy of chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) may be both a predictive factor for chemoresistance in patients with LUAD and a potential target positively selected in resistant cells. By using biopsies from patients with LUAD, KRAS-mutant LUAD cell lines, and in vivo genetically engineered KRAS-driven mouse models, we evaluated the role of DDR1 in the context of chemotherapy treatment. We found that DDR1 is upregulated during chemotherapy both in vitro and in vivo. Moreover, analysis of a cohort of patients with LUAD suggested that high DDR1 levels in pretreatment biopsies correlated with poor response to chemotherapy. Additionally, we showed that combining DDR1 inhibition with chemotherapy prompted a synergistic therapeutic effect and enhanced cell death of KRAS-mutant tumors in vivo. Collectively, this study suggests a potential role for DDR1 as both a predictive and prognostic biomarker, potentially improving the chemotherapy response of patients with LUAD.}, number = {15}, doi = {10.1172/jci.insight.137869}, url = {https://doi.org/10.1172/jci.insight.137869}, }